In vivo profiling for oral candidiasis drug target discovery

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$724,482.00
Award Year:
2009
Program:
SBIR
Phase:
Phase II
Contract:
2R44DE017033-02A1
Award Id:
76134
Agency Tracking Number:
DE017033
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
GUILD ASSOCIATES, INC., 5750 SHIER-RINGS RD, DUBLIN, OH, 43016
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
001004258
Principal Investigator:
DAVIDSCHOFIELD
(843) 573-0095
DSCHOFIELD@GUILDASSOCIATES.COM
Business Contact:
ROBERTFREEBURN
() -
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Candida albicans is the most frequently isolated fungal pathogen of humans and represents an important public health problem. However, antifungal treatments are hampered by emerging resistance, toxicity concerns, lack o f fungicidal activity, and narrow spectrum of action. Thus, there is a critical need for new antifungal drug targets, and new antifungal drug strategies. An important step in the identification of new targets for antifungal drug discovery is the use of in vivo genome profiling using appropriate diseased samples to identify fungal-specific genes which are required for infection. The Phase I application successfully utilized emerging technologies to identify C. albicans genes induced during murine oral candid iasis. Specifically, we identified a subset of: (i) in vivo expressed genes; (ii) infection and colonization-associated genes, and (iii) novel and fungal-specific genes that will likely play a role in the transition from comced targets identified during th e Phase I research are required for oral infection. Specific C. albicans knockout strains will be generated and assessed for their ability to cause disease during oral candidiasis. Specific Aim 2 will demonstrate that oligonucleotides can function as antif ungal agents against Candida species in vitro. Oligonucleotides will be designed against pre-existing antifungal drug targets and against infection- required targets identified in Specific Aim 1. The oligonucleotides will be preferentially designed against domains within the gene open reading frame that are conserved amongst pathogenic fungi. The antifungal capability of the oligonucleotides will be assessed specifically at the mRNA level, and analyzed for the corresponding alterations in growth, viability, or specific phenotype trait. Specific Aim 3 will demonstrate that the oligonucleotides can be used alone, and in combination with known antifungal agents, to treat murine oral candidiasis. The rese Mucosal candidiasis is the mostcommon type of Candida inf ection and occurs frequently in immunocompromised patients, and patients with an altered bacterial flora. Despite the large number of at risk patients, antifungal treatment is hampered by toxic side effects and emerging antifungal resistant Candida strains and species.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government